Fig. 7: Schematic model showing the role of RAS inhibitors in SpA-associated bone changes. | Experimental & Molecular Medicine

Fig. 7: Schematic model showing the role of RAS inhibitors in SpA-associated bone changes.

From: Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis

Fig. 7

a Osteoclast and osteoblast differentiation increased in r-axSpA, possibly because of the increase in the expression of RAS molecules, culminating in aberrant bone formation and erosion. b An ARB inhibited the binding of Ang II and Ang 1-7 to AT1R, resulting in the suppression of osteoclast and osteoblast differentiation. c An ACEi inhibited the conversion of Ang I into Ang II and augmented the production of Ang 1-7, leading to increased osteoblast and osteoclast differentiation, which caused higher bone formation and erosion. Ang, angiotensin; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; AT1R, angiotensin II type 1 receptor; RAS, renin-angiotensin system; r-axSpA, radiographic axial spondyloarthritis.

Back to article page